DIAGNOS Announces Further Deployment of its AI based CARA Technology in Saudi Arabia
03 February 2021 - 1:30AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB: DGNOF) a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce that it will be deploying
its AI medical test for retina analysis at the Enayah Mobile Smart
Eye Clinics operated by the Association of Charitable Health
Society for Patient Care (known as “Enayah”), in collaboration with
its Saudi business partner, Kanhoor Medical Co. (“Kanhoor”).
Enayah is one of the pioneers of humanitarian
societies in the Kingdom of Saudi Arabia and is registered in the
Ministry of Labor & Social Development. Its mission is to
provide healthcare workers and lower income patients with quality
healthcare. As part of their program known as “Combating
Blindness”, Enayah will be deploying and operating a fleet of
remote Mobile Smart Eye Clinics to increase accessibility to eye
care for communities and patients with reduced mobility.
“For almost three years, Enayah has been using
DIAGNOS’ AI based CARA platform successfully to screen thousands of
diabetic patients for diabetic retinopathy with an early detection
test. By using DIAGNOS’ telemedicine solution we have been able to
identify patients needing care early so their vision can be saved.
As part of our “Combating Blindness” program, we are extremely
pleased to extend this service and add it to other tests in our
fleet of vans of Mobile Smart Eye Clinics”, said Dr. Salman
Abdullah Al-Mutairi, Executive Director of Enayah Charitable
Association and Secretary General of the council of Private
Association in the Kingdom.
“Diabetes is the largest cause of vision loss in
the world and accessibility to an eye test such as this is one of
the most important factors contributing to early diagnosis and
treatment. We applaud Dr. Salman's initiative to bring eye
screening to remote communities with mobile clinics”, said
Yves-Stéphane Couture, Vice President of Sales for
DIAGNOS.
“We salute this new innovative engagement from
Enayah and their contribution to bring care to remote communities
and to patients with reduced mobility. Technology is working
towards bringing down barriers for all to have access to quality
healthcare and we are proud to bring this initiative to Saudi
Arabia. To that effect, CARA is now hosted locally at Saudi Telecom
(STC) Cloud Services with the collaboration of Hajz Telecom”, said
Abdul-Aziz Rashid Al-Mugait, General Manager of Kanhoor
Medical Co.
About Kanhoor Medical CoAl Kanhoor is focused on
selling telemedicine and AI assisted application in KSA. Al Kanhoor
is providing technology for remote patient observation and
marketing Diagnos suit of products in KSA and beyond. Al Kanhoor is
a sister company of HAJZTELECOM “HTC” Technology & Telecom
solutions provider and contractor to Saudi Telecom - STC-
contractor since 1997.
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based of its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s AI-based image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com.
This press release contains forward-looking
information. We cannot guarantee that the forward-looking
information mentioned will prove to be accurate, as there may be a
significant discrepancy between actual results or future events and
those mentioned in this statement. DIAGNOS disclaims any intention
or obligation to publicly update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise. The forward-looking information contained in this
press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024